Table 2 |
||
|
Initial clinical manifestations in PR3/MPO-ANCA-positive patients with idiopathic vasculitides and antithyroid DIDs |
||
| Patients with idiopathic vasculitides (n = 56) |
Patients with antithyroid DIDs (n = 16) |
|
|
|
||
| Systemic |
56 (100) |
16 (100) |
| Arthralgia/myalgia |
56(100) |
16 (100) |
| Fever >38.5°C |
48 (86) |
4 (25)*** |
| Weight loss >2 kg a month |
47 (84) |
5 (31)*** |
| Renal |
42 (75) |
3 (19)*** |
| Acute renal failure |
25 (45) |
1(6)** |
| Proteinuria, hematuria |
17 (30) |
2 (12) |
| Lung |
28 (50) |
3 (19)* |
| Infiltrate |
15 (27) |
2 (12) |
| Nodules |
10 (18) |
1 (6) |
| hemoptysis |
14 (25) |
1 (6) |
| Pulmonary-renal syndrome |
22 (39) |
1 (6)* |
| Skin |
14 (25) |
10 (62.5)** |
| Necrosis |
11(20) |
2 (12) |
| Gangrene |
3 (5) |
0 |
| Purpura |
5 (9) |
1 (6) |
| Urticaria-like vasculitis |
0 |
5 (31) *** |
| Urticaria |
0 |
2 (12.5)* |
| Gastrointestinal tract |
7 (12) |
0 |
| Ear, nose |
15 (27) |
0* |
| Eyes |
7 (12) |
0 |
| Nervous system |
26 (46) |
1 (6)** |
| Central |
13 (20) |
0 |
| Peripheral |
15 (27) |
1 (6) |
|
|
||
|
All values represent numbers of patients (%). *p < 0.05 **p < 0.01 ***p < 0.001. ANCA, antineutrophil cytoplasmic antibodies; DID, drug-induced autoimmune disease; MPO, myeloperoxidase; PR3, proteinase 3. |
||
|
Bonaci-Nikolic et al. Arthritis Research & Therapy 2005 7:R1072 doi:10.1186/ar1789 |
||
